Drugs / KK2845
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06812104 | Oct 2024 → Nov 2031 expected | refractory hematologic cancer | Kyowa Kirin, Inc. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KK2845 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06812104 ↗ |